Table 1.
Cohort characteristics
| Total (n = 2082) | APC | Biallelic MUTYH | Monoallelic MUTYH | |
|---|---|---|---|---|
| Male—n (%) | 1202 (58%) | 147 (50%) | 64 (54%) | 27 (69%) |
| Adenoma count | ||||
| 0 | 336 | 13 (3.9%) | 3 (0.9%) | 7 (2.1%) |
| 1–9 | 328 | 1 (0.3%) | 6 (1.8%) | 7 (2.1%) |
| 10–19 | 406 | 3 (0.7%) | 6 (1.5%) | 7 (1.7%) |
| 20–49 | 590 | 50 (8.5%) | 60 (10%) | 15 (2.5%) |
| 50–99 | 122 | 15 (12%) | 22 (18%) | 3 (2.5%) |
| >100 | 300 | 211 (70%) | 22 (7.3%) | 0 (0%) |
| Mean age at adenoma diagnosis (min–max) | 53 (4–84) | 36 (9–68) | 49 (21–75) | 54 (23–77) |
| CRC, yes | 746 (36%) | 57 (7.6%) | 82 (11%) | 15 (2.0%) |
| Mean age at (first) CRC diagnosis (min–max) | 53 (12–91) | 41 (21–58) | 49 (21–76) | 57 (28–91) |
| FAP extracolonic manifestations, yes | 200 (10%) | 43 (22%) | 8 (4.0%) | 4 (2.0%) |
| FDR with polyps | 728 (38%) | 156 (21%) | 46 (6.3%) | 18 (2.5%) |
| Missing | 164 (8%) | 12 (7.3%) | 4 (2.4%) | 1 (0.6%) |
| FDR with CRC | 811 (42%) | 76 (9.7%) | 42 (5.1%) | 26 (3.2%) |
| Missing | 164 (8%) | 12 (7.3%) | 4 (2.4%) | 1 (0.6%) |